Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T15:42:27.007Z.
Calculation as of: 2026-10-06T15:42:27.007Z.
Quote observation: 2026-10-06T15:38:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 93c5e63ae445a2e41424364838d154d4df2cbb6a4085a726ee5a5ae15b1ce67b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$63.78M
PS Ratio
N/A
TTM Avg
1001.33
3Y Avg
388.48
5Y Avg
284.97
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $63.30M | N/A | N/A | N/A | N/A |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A | N/A | N/A | N/A |
| InterCure Ltd. (INCR)vs › | $63.02M | 0.79 | 0.69 | 0.95 | 1.63 |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.78M | N/A | 1001.33 | 388.48 | 284.97 |
| Heron Therapeutics, Inc. (HRTX)vs › | $63.98M | 0.42 | 0.98 | 1.84 | 3.07 |
| Adicet Bio, Inc. (ACET)vs › | $61.18M | N/A | 16.03 | 122.62 | 125.37 |
| Cingulate Inc. (CING)vs › | $66.40M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $65.87M | 1.24 | 6.22 | 5.05 | 5.05 |
| MiNK Therapeutics, Inc. (INKT)vs › | $60.58M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.47M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-30 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
